Gilead Sciences Target of Unusually Large Options Trading (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) saw some unusual options trading activity on Monday. Traders acquired 12,503 call options on the stock. This represents an increase of 54% compared to the average volume of 8,104 call options.

Insiders Place Their Bets

In other news, CFO Andrew Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the sale, the chief financial officer owned 165,646 shares in the company, valued at $22,918,780.56. This trade represents a 1.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the transaction, the director owned 10,066 shares in the company, valued at $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 99,000 shares of company stock worth $13,747,860. 0.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently bought and sold shares of GILD. BlackRock Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $15,393,785,000. State Street Corp lifted its stake in Gilead Sciences by 1.9% during the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock worth $7,393,921,000 after purchasing an additional 1,151,213 shares during the last quarter. Norges Bank acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $2,617,152,000. Invesco Ltd. boosted its holdings in Gilead Sciences by 2.9% in the fourth quarter. Invesco Ltd. now owns 15,584,341 shares of the biopharmaceutical company’s stock valued at $1,912,822,000 after purchasing an additional 444,660 shares in the last quarter. Finally, Amundi increased its stake in Gilead Sciences by 10.7% in the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after purchasing an additional 1,018,976 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on GILD shares. Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a report on Wednesday, August 5th. Needham & Company LLC reissued a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research report on Wednesday, August 5th. Daiwa Securities Group cut their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Finally, Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $158.78.

Gilead Sciences Stock Down 0.1%

GILD stock opened at $146.30 on Wednesday. The company’s 50 day moving average price is $139.02 and its 200 day moving average price is $136.18. The firm has a market capitalization of $181.41 billion, a price-to-earnings ratio of -54.79 and a beta of 0.33. Gilead Sciences has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. On average, equities research analysts anticipate that Gilead Sciences will post -0.48 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is -122.85%.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Expanded access for lenacapavir: Gilead and the Pan American Health Organization agreed to improve access to Gilead’s twice-yearly HIV-prevention drug lenacapavir in Latin America and the Caribbean. The agreement supports broader adoption of the treatment and reinforces Gilead’s leadership in HIV prevention, although near-term financial terms were not disclosed. Reuters article
• Positive Sentiment: Continued shareholder returns: Gilead’s $0.82-per-share cash dividend is payable September 29. The distribution highlights the company’s cash-generation profile and may support income-focused demand for GILD, even though the stock typically adjusts for the dividend on the ex-dividend date. Dividend analysis
• Neutral Sentiment: Healthcare conference update: Gilead presented at Morgan Stanley’s Global Healthcare Conference, keeping investor attention on its HIV portfolio, pipeline and research investments. The available report is a transcript rather than a clearly identified new financial forecast. Conference transcript
• Neutral Sentiment: Market and trading factors: GILD recently gained while the broader market declined, suggesting relative defensive strength. Unusually high call-option activity also indicates increased bullish positioning, but options flows can be speculative and do not change fundamentals. Market performance article
• Negative Sentiment: Valuation and dividend adjustment risks: After a substantial five-year share-price advance, investors are questioning whether Gilead’s sales growth adequately supports its valuation. The September 15 ex-dividend date can also mechanically weigh on the stock, while the company’s elevated debt relative to equity remains a balance-sheet consideration. Valuation analysis

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.